文献速递中医内科中药与中成药合理使用

鸦胆子油乳注射液联合支持治疗难治性晚期结直肠癌:一项初步随机对照试验方案

Brucea javanica oil emulsion plus supportive care for refractory advanced colorectal cancer: a pilot RCT protocol.
PubMed 文献 · Front Pharmacol · 2025-07-21

本研究为多中心、随机对照试验方案,计划纳入60例对现有所有治疗均难治的晚期结直肠癌患者,按1:1随机分为鸦胆子油乳注射液联合最佳支持治疗组与单纯最佳支持治疗组,主要结局为无进展生存期,旨在为III期临床试验提供初步数据。

要点

  • 鸦胆子油乳注射液联合最佳支持治疗用于难治性晚期结直肠癌。
  • 主要结局为无进展生存期,次要结局包括临床症状、生活质量和总生存期。
  • 治疗持续至疾病进展或毒性不可耐受,每2个月随访至死亡、失访或随机后12个月。

核心结论

  • 该试验旨在收集初步数据,为评估鸦胆子油乳注射液联合最佳支持治疗在难治性晚期结直肠癌中疗效与安全性的III期临床试验提供依据。

研究设计与样本

  • 多中心、随机、对照临床试验方案,计划纳入60例符合条件的晚期结直肠癌患者,按1:1随机分配至实验组或对照组。
  • 实验组接受鸦胆子油乳注射液联合最佳支持治疗,对照组仅接受最佳支持治疗。

关键数值与推荐

  • 主要结局指标为无进展生存期(PFS)。
  • 次要结局指标包括临床症状、生活质量、总生存期(OS),并详细记录不良事件(AEs)。
  • 治疗持续至疾病进展或毒性不可耐受,每2个月随访一次,直至患者死亡、失访或随机后12个月。

临床怎么用

  • 该方案尚处于试验阶段,结果未报告,暂不能形成临床推荐。

局限性

  • 该文件为试验方案,尚未报告实际研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colorectal cancer (CRC) is a significant contributor to global mortality. However, the existing therapeutic approaches often fall short of achieving favorable outcomes especially in metastatic CRC. Brucea javanica Oil Emulsion Injection (BJOEI) as adjuvant therapy also showed superiority for cancer treatment in clinical practice. This trial aims to gather preliminary data to inform a phase III clinical trial evaluating the efficacy and safety of BJOEI in combination with best supportive care (BSC) for patients with advanced colorectal cancer who are refractory to all existing therapies. METHODS: The study is designed as a multicenter, randomized, and controlled clinical trial. 60 eligible participants will be randomly assigned to the experimental or control group in a ratio of 1:1. The experimental group will receive BJOEI and BSC, while the control group will undergo BSC. The treatment will cease upon disease progression or when toxicity becomes intolerable. Follow-up assessments will be scheduled every 2 months, continuing until the patient dies, is lost to follow-up, or reaches 12 months post-randomization. The main outcome measured will be progression-free survival (PFS). Additional outcomes to be evaluated are clinical symptoms, quality of life, and overall survival (OS). Detailed records of adverse events (AEs) will be maintained. EXPECTED OUTCOMES: To the best of our knowledge, this is the first study to investigate the use of Traditional Chinese Medicine as a monotherapy in patients with advanced colorectal cancer who have failed multiple lines of standard treatment. TRIAL REGISTRATION: Clinicaltrials.gov, NCT05897749. Registered on 09 May 2023.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Fang L, Wang Y, Fang Y, et al. Brucea javanica oil emulsion plus supportive care for refractory advanced colorectal cancer: a pilot RCT protocol. Front Pharmacol. 2025. PMID: 40761400. doi:10.3389/fphar.2025.1610575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。